New study finds Glivec® demonstrated substantially greater molecular response than traditional treatment
Molecular response is possible new benchmark for evaluating success of chronic myeloid leukemia treatment, suggest authors of study in New England Journal of Medicine
Basel, Switzerland, 9 October 2003 - Monitoring response at a molecular level may provide a new benchmark in the management of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and may ultimately play a role in optimizing treatment, suggest authors of a study published today in the New England Journal of Medicine (NEJM). The study demonstrated that Glivec® (imatinib)* produced a substantially greater molecular response than a traditional combination therapy in patients with newly diagnosed Ph+ CML in the chronic phase.
Please see full press release under the following link:
